Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ADTX - Aditxt stock rises as manufacturing of immunotherapy begins for planned psoriasis trial

ADTX - Aditxt stock rises as manufacturing of immunotherapy begins for planned psoriasis trial

ADiTx Therapeutics Inc.

  • Aditxt ( NASDAQ: ADTX ) stock rose ~7% on Friday after the company said its program Adimune started the GMP manufacturing of immunotherapy drug candidate ADI-100 for its first-in-human trials in H2 2023.
  • Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied, the company added.
  • Aditxt noted that its Adimunes nucleic acid-based technology called Apoptotic DNA Immunotherapy (ADI) restores/induces immune tolerance in an antigen-specific way and potentially has efficacy benefit without immune suppression.

For further details see:

Aditxt stock rises as manufacturing of immunotherapy begins for planned psoriasis trial
Stock Information
Company Name: ADiTx Therapeutics Inc.
Stock Symbol: ADTX
Market: NASDAQ
Website: aditxt.com
Menu
ADTX ADTX Quote ADTX Short ADTX News ADTX Articles ADTX Message Board
Get ADTX Alerts

News, Short Squeeze, Breakout and More Instantly...